Posted by Michael Wonder on 03 May 2022
CMS’s decision to restrict coverage of Aduhelm very unlikely to impact other accelerated approvals in other classes
2 May 2022 - CMS Administrator, Chiquita Brooks-LaSure, said last week that CMS will continue to reimburse drugs approved by the FDA fast track accelerated approval pathway.
Despite the recent national coverage determination that resulted in severe limitations on coverage of Aduhelm (aducanumab), restrictions on accelerated approval drugs will be “very rare,” according to Brooks-LaSure.
